Which Long-Acting Basal Insulin to Start
Start with insulin glargine, insulin detemir, or insulin degludec—all are preferred over NPH insulin to reduce hypoglycemia risk, with longer-acting formulations (glargine U300 or degludec U100/U200) offering additional advantages for patients at higher hypoglycemia risk. 1
Preferred Basal Insulin Options
The 2023 American Association of Clinical Endocrinology guidelines explicitly state that analog insulins, including detemir, glargine, or degludec are preferred over human insulins such as neutral protamine Hagedorn (NPH) to reduce hypoglycemia 1. This represents the current standard of care based on consistent evidence demonstrating lower rates of symptomatic and nocturnal hypoglycemia with analog insulins 2, 3.
First-Generation vs. Second-Generation Analogs
- First-generation analogs (glargine U100, detemir) effectively reduce hypoglycemia compared to NPH insulin 2, 3
- Second-generation analogs (glargine U300, degludec U100/U200) provide even greater stability with lower nocturnal hypoglycemia risk compared to glargine U100 1, 2
- Longer-acting formulations require slower titration (≥3 days for glargine U300 and degludec) due to longer time to steady state 1
Specific Clinical Scenarios
Standard Initiation
For most patients initiating basal insulin, any of the analog insulins (detemir, glargine U100, glargine U300, or degludec) are appropriate first choices 1. The selection should prioritize:
- Hypoglycemia risk: Choose glargine U300 or degludec for patients at higher risk (elderly, renal impairment, hypoglycemia unawareness) 2, 4, 5
- Dosing flexibility: Degludec offers the most flexible dosing window if adherence to strict timing is challenging 4, 5
- Cost considerations: NPH insulin remains an acceptable option when cost is prohibitive, though it carries higher hypoglycemia risk 6, 3
High-Dose Requirements
For patients requiring large insulin doses (>0.5 units/kg/day or >200 units/day):
- Concentrated formulations (glargine U300, degludec U200) allow administration of higher doses in smaller volumes 6
- These formulations may improve absorption and adherence 4, 5
Hospitalized Patients
In non-critical care hospital settings, glargine or detemir given once or twice daily are recommended over NPH 7. Detemir or NPH can be given twice daily if needed 7.
Dosing Algorithm
Initial dose calculation 1:
- A1C <8%: Start at 0.1-0.2 units/kg/day
- A1C ≥8%: Start at 0.2-0.3 units/kg/day
- Alternative: Start with 10 units daily regardless of weight 6, 8
Titration schedule 1:
- Standard analogs (glargine U100, detemir, NPH): Titrate every 2-3 days
- Longer-acting analogs (glargine U300, degludec): Titrate every 3-5 days due to longer half-life 1, 2
Titration adjustments based on fasting blood glucose 1:
- FBG >180 mg/dL: Increase by 20% of total daily dose
- FBG 140-180 mg/dL: Increase by 10% of total daily dose
- FBG 110-139 mg/dL: Increase by 1 unit
- FBG <70 mg/dL: Decrease by 10-20%
- FBG <40 mg/dL: Decrease by 20-40%
Critical Considerations
Switching Between Formulations
When switching between basal insulins, most can be converted unit-for-unit with subsequent adjustment based on glucose monitoring 2. However, reduce initial dose by 10-20% when switching from detemir or glargine U300 to another insulin, particularly in patients with tight glycemic control or high hypoglycemia risk 2.
Avoiding Overbasalization
Do not continue escalating basal insulin doses beyond 0.5-1.0 units/kg/day without meaningful FBG reduction 2, 3, 8. Signs of overbasalization include 2, 3:
- Bedtime-to-morning glucose differential ≥50 mg/dL
- Hypoglycemia (aware or unaware)
- High glucose variability
When these occur, re-evaluate the treatment plan and consider adding prandial insulin or GLP-1 receptor agonist rather than further increasing basal insulin 2, 3.
Concomitant Medications
After initiating basal insulin, discontinue sulfonylureas to reduce hypoglycemia risk 1. Continue metformin, as the combination reduces weight gain and insulin requirements 7, 3.